A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women
Study identifier:1033IL/0030
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Feb 1996
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
